0001213900-23-022948.txt : 20230327 0001213900-23-022948.hdr.sgml : 20230327 20230327070532 ACCESSION NUMBER: 0001213900-23-022948 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230327 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230327 DATE AS OF CHANGE: 20230327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Augmedix, Inc. CENTRAL INDEX KEY: 0001769804 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 833299164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40890 FILM NUMBER: 23761427 BUSINESS ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISC STATE: CA ZIP: 94104 BUSINESS PHONE: 561-989-2208 MAIL ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISC STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Malo Holdings Corp DATE OF NAME CHANGE: 20190305 8-K 1 ea175782-8k_augmedix.htm CURRENT REPORT
0001769804 false 0001769804 2023-03-27 2023-03-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 27, 2023

 

 

 

AUGMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40890   83-3299164

(State or other jurisdiction

of incorporation)

  

(Commission File Number) 

  

(I.R.S. Employer

Identification No.) 

 

111 Sutter Street, Suite 1300, San Francisco, California 94104

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (888) 669-4885

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   AUGX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On March 27, 2023, Augmedix, Inc., a Delaware corporation (the “Company”), released its financial results for the fourth quarter and fiscal year ended December 31, 2022. The press release announcing the release of financial results is furnished as Exhibit 99.1 and is incorporated herein by reference.

 

The information provided in this Item 2.02, including Exhibit 99.1, is intended to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.		   Description
99.1   Press release dated March 27, 2023 announcing fourth quarter and fiscal year 2022 financial results.
     
104   Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AUGMEDIX, INC.
     
Dated: March 27, 2023 By: /s/ Paul Ginocchio
    Paul Ginocchio
    Chief Financial Officer

 

 

 2

 

 

 

 

 EX-99.1 2 ea175782ex99-1_augmedix.htm PRESS RELEASE DATED MARCH 27, 2023 ANNOUNCING FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS

Exhibit 99.1 

 

 

Augmedix Reports Strong Commercial Traction and Sales Momentum;

 

Reports Fourth Quarter and Full Year 2022 Financial Results

 

SAN FRANCISCO, Calif. –– March 27, 2023 –– Augmedix (Nasdaq: AUGX), a leading provider of ambient medical documentation and data solutions delivered remotely to healthcare systems, physician practices, hospitals, and telemedicine practitioners, today reported financial results for the three and 12 months ended December 31, 2022.

 

“We finished 2022 with our best-ever fourth quarter in terms of bookings, with sales momentum continuing into 2023 with record first-quarter bookings, including our largest-ever clinician cohort signed,” said Manny Krakaris, Chief Executive Officer at Augmedix. “Our expanding portfolio of products has positioned us well for the large market opportunity in front of us, and we look forward to delivering strong results in 2023 with improving operating leverage.”

 

Continued Krakaris, “Our innovative technology is engineered to relieve the documentation burden for clinicians, allows the patient and doctor to truly connect at the point of care, and structures the visit data that ultimately improves future outcomes for patients and healthcare providers. We operate at the nexus of the critical issues impacting large health systems and US healthcare overall, which are patient access, patient outcomes, and the cost curve. Helping health systems solve these big issues is leading to larger engagements and increased interest from both existing and new systems, as shown by our recent wins. Our development efforts are focused on delivering innovative products that can affect behavior at the point of care to drive better outcomes at scale so that we make a meaningful impact on the industry.”

 

Fourth Quarter 2022 Financial and Operational Highlights

 

All comparisons, unless otherwise noted, are to the three months ended December 31, 2021.

 

●Augmedix added one new region of an existing health enterprise with a large cohort of new clinicians in the fourth quarter of 2022, had two major expansions at existing clients, and expanded services with a top 10 health system that was initially won in early 2022.

 

●We are testing Augmedix Go with a number of clinicians, including several at a large health system.

 

●We are now integrated with a select number of EHRs, including an EPIC integration with a major health system.

 

●Total revenue was $8.8 million, slightly stronger than our January pre-announcement and an increase of 33% compared to $6.6 million.

 

●Dollar-based Net Revenue Retention was 126% for our Health Enterprise customers compared to 136%.

 

●GAAP Gross Profit increased 38% to $4.0 million from $2.9 million.

 

●GAAP Gross Margin increased 160 basis points to 46.3% compared to 44.7%, and increased 60 basis points from 45.7% reported in the third quarter of 2022.

 

●GAAP Operating Expenses increased 25% to $9.5 million compared to $7.6 million. Adjusted operating expenses, which excludes stock-based compensation and one-time items in both periods, grew 26% to $8.8 million compared to $7.0 million.

 

 

 

 

●GAAP Net Loss was $5.6 million compared to $5.3 million.

 

●EBITDA loss was $4.9 million compared to $4.4 million. Adjusted EBITDA loss was $4.2 million compared to $3.7 million, which excludes stock-based compensation in both periods and one-time transaction costs, and a compensation accrual catch-up. Adjusted EBITDA loss again declined sequentially from the $4.5 million reported in the third quarter of 2022 and the $5.3 million reported in the second quarter of 2022.

 

●Cash and restricted cash as of December 31, 2022, was $22.0 million compared to $41.6 million as of December 31, 2021.

 

Full Year 2022 Financial and Operational Highlights

 

All comparisons, unless otherwise noted, are to the 12 months ended December 31, 2021.

 

●Total revenue was $30.9 million, an increase of 40% compared to $22.2 million.

 

●Dollar-based Net Revenue Retention was 128% for our Health Enterprise customers compared to 124%.

 

●GAAP Gross Profit increased 39% to $14.0 million from $10.0 million.

 

●GAAP Gross Margin was flat at 45.1% compared to 45.1% as increased exposure to U.S.-serviced clinicians, who have the highest cost of revenue, offset efficiency gains elsewhere.

 

●GAAP Operating Expenses were $36.3 million compared to $27.6 million. Adjusted operating expenses, which excludes stock-based compensation and one-time items in both periods, grew 31% to $34.3 million compared to $26.3 million.

 

●GAAP Net Loss was $24.4 million compared to $17.5 million.

 

●EBITDA loss was $21.8 million compared to $14.5 million. Adjusted EBITDA loss, which excludes stock-based compensation in both periods and one-time items such as transaction related expenses, the compensation accrual catch-up, PPP loan forgiveness and loss on extinguishment of our prior debt facility, increased to $18.6 million from $15.2 million.

 

Adjusted gross margin, Adjusted operating expenses, EBITDA and Adjusted EBITDA are Non-GAAP financial measures. See “Non-GAAP Financial Measures.”

 

2023 Revenue Guidance

 

Based on the strong finish to 2022 and the momentum that has continued into the first quarter of 2023, Augmedix expects to generate approximately $42 million of revenue in 2023.

 

Conference Call

 

Augmedix will host a conference call at 5:00 a.m. PT / 8:00 a.m. ET today, Monday, March 27, 2022, to discuss its fourth quarter and full year 2022 financial results. The conference call can be accessed by dialing + 1-877-407-3982 for U.S. participants or +1 (201) 493-6780 for international participants and referencing conference ID # 13726968. Interested parties may access a live and archived webcast of the event on the “Investor Relations” section of the Company’s website at: ir.augmedix.com.

 

2

 

 

Definition of Key Metrics

 

Dollar-Based Net Revenue Retention: We define a “Health Enterprise” as a company or network of doctors that has at least 50 clinicians currently employed or affiliated that could utilize our services. Dollar-based net revenue retention is determined as the revenue from Health Enterprises as of twelve months prior to such period end as compared to revenue from these same Health Enterprises as of the current period end, or current period revenue. Current period revenue includes any expansion or new products and is net of contraction or churn over the trailing twelve months but excludes revenue from new Health Enterprises in the current period. We believe growth in dollar-based net revenue retention is a key indicator of the performance of our business as it demonstrates our ability to increase revenue across our existing customer base through expansion of users and products, as well as our ability to retain existing customers.

 

Average Clinicians in Service: We define a clinician in service as an individual doctor, nurse practitioner or other healthcare professional using our products. We average the month-end number of clinicians in service for all months in the measurement period and the number of clinicians in service at the end of the month immediately preceding the measurement period. We believe growth in the average number of clinicians in service is a key indicator of the performance of our business as it demonstrates our ability to penetrate the market and grow our business.

 

About Augmedix

 

Augmedix is on a mission to help clinicians and patients form a human connection at the point of care with seamless technology. Augmedix’s proprietary Notebuilder Platform extracts relevant data from natural clinician-patient conversations and converts that data into medical notes in real time, which are seamlessly transferred to the EHR. The company’s platform uses Automatic Speech Recognition, Natural Language Processing, including Large Language Models, and Medical Documentation Specialists to generate accurate and timely medical notes to healthcare providers. Leveraging this platform, Augmedix’s products relieve clinicians of administrative burden, in turn, reducing burnout and increasing both clinician and patient satisfaction. Augmedix is also leading the revolution in leveraging point-of-care data by making connections between millions of physician-patient interactions and analyzing them to deliver actionable insights that elevate patient care. Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit www.augmedix.com.

 

Non-GAAP Financial Measures

 

To supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: adjusted cost of revenue, adjusted gross profit, adjusted gross margin, adjusted operating expenses, EBITDA, and adjusted EBITDA. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

 

3

 

 

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results, like one-time transaction costs related to the reverse merger and OTC listing. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to our historical performance and liquidity as well as comparisons to our competitors’ operating results. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business.

 

There are a number of limitations related to the use of non-GAAP financial measures. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures and evaluating these non-GAAP financial measures together with their relevant financial measures in accordance with GAAP.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” that involve a number of risks and uncertainties. Words such as “believes,” “may,” “will,” “estimates,” “potential,” “continues,” “anticipates,” “intends,” “expects,” “could,” “would,” “projects,” “plans,” “targets,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding sales momentum continuing into 2023 with record first-quarter bookings; our expanding portfolio of products positioning us well for the large market opportunity in front of us; our looking forward to delivering strong results in 2023 with improving operating leverage; our helping of health systems leading to larger engagements and increased interest from both existing and new systems; our development efforts focused on delivering innovative products so that we make a meaningful impact on the industry; the momentum that has continued into the first quarter of 2023; and our expectation to generate approximately $42 million of revenue in 2023. Forward-looking statements are based on management’s expectations as of the date of this filing and are subject to a number of risks, uncertainties and assumptions, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in our most recent Form 10-K filed with the Securities and Exchange Commission on March 30, 2022 as well as other documents that may be filed by us from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: our expectations regarding changes in regulatory requirements; our ability to interoperate with the electronic health record systems of our customers; our reliance on vendors; our ability to attract and retain key personnel; the competition to attract and retain remote documentation specialists; anticipated trends, growth rates, and challenges in our business and in the markets in which we operate; our ability to further penetrate our existing customer base; our ability to protect and enforce our intellectual property protection and the scope and duration of such protection; developments and projections relating to our competitors and our industry, including competing dictation software providers, third-party, non-real time medical note generators and real time medical note documentation services; the impact of current and future laws and regulations; the impact of the COVID-19 crisis on our business, results of operations and future growth prospects. Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

 

Investors:

Matt Chesler, CFA

FNK IR

investors@augmedix.com

 

Media:

Kaila Grafeman

Augmedix

pr@augmedix.com

 

4

 

 

AUGMEDIX, INC.

Condensed Consolidated Statements of Operations

(Unaudited, in thousands except Average Clinicians in Service)

 

   Three Months Ended   Year Ended 
   December 31,   December 31, 
   2022   2021   2022   2021 
Revenue  $8,751   $6,577   $30,933   $22,165 
Cost of revenues   4,702    3,640    16,979    12,158 
Gross profit   4,049    2,937    13,954    10,007 
Operating expenses                    
General and administrative   4,538    3,772    16,893    13,759 
Sales and marketing   2,339    1,876    9,283    7,121 
Research and development   2,612    1,943    10,149    6,678 
Total operating expenses   9,489    7,591    36,325    27,558 
Loss from operations   (5,440)   (4,654)   (22,371)   (17,551)
                     
Other income (expense), net   (159)   (624)   (2,078)   87 
Net loss  $(5,599)  $(5,278)  $(24,449)  $(17,464)
                     
Average Clinicians in Service   1,246    881    1,093    750 
                     
Share Count   37,435    34,655    37,420    28,915 

 

5

 

 

AUGMEDIX, INC.

Reconciliation of GAAP to Non-GAAP Metrics

(Unaudited, in thousands)

 

   Three Months Ended   Year Ended 
   December 31,   December 31, 
Stock Based Compensation Expense  2022   2021   2022   2021 
Cost of revenues  $22   $20   $89   $95 
General and administrative   553    284    1,527    935 
Sales and marketing   52    29    173    116 
Research and development   92    61    323    241 
Total stock-based compensation expense  $719   $394   $2,112   $1,387 
                     
Net loss  $(5,599)  $(5,278)  $(24,449)  $(17,464)
Interest expense   373    613    1,675    2,252 
Tax   80    47    120    47 
Depreciation and Amortization   249    169    855    691 
EBITDA  $(4,897)  $(4,449)  $(21,799)  $(14,474)
Stock-based Compensation Expense   719    394    2,112    1,387 
Transaction Related Expense   -    -    -    (73)
Less: PPP Loan Forgiveness   -    -    -    (2,180)
Loss on Extinguishment of Debt Facility   -    -    1,097    - 
Less: Lease Provision Write Off   -    -    -    (259)
Post Employment Benefit Fund Catchup   -    391    -    391 
Adjusted EBITDA  $(4,178)  $(3,664)  $(18,590)  $(15,208)
                     
GAAP Cost of Revenues  $4,702   $3,640   $16,979   $12,158 
Less: Stock-based Compensation Expense   22    20    89    95 
Lease Provision Write Off   -    -    -    (82)
Less: Post Employment Benefit Fund Catchup   -    153    -    153 
Adjusted cost of revenues   4,680    3,467    16,890    11,992 
Non-GAAP Gross Profit  $4,071   $3,110   $14,043   $10,173 
Adjusted Gross Margin   46.5%   47.3%   45.4%   45.9%
                     
GAAP Operating Expenses  $9,489   $7,591   $36,325   $27,558 
Less: Stock-based Compensation Expense   697    374    2,023    1,292 
Lease Provision Write Off   -    -    -    (177)
Less: Post Employment Benefit Fund Catchup   -    238    -    238 
Less: Transaction Related Expense   -    -    -    (73)
Non-GAAP Operating Expenses  $8,792   $6,979   $34,302   $26,278 

 

6

 

 

AUGMEDIX, INC.

Condensed Consolidated Balance Sheet

(Unaudited, in thousands)

 

   Year Ended 
   December 31, 
   2022   2021 
Assets        
Cash & Cash Equivalents  $21,988   $41,587 
Accounts Receivables   6,354    7,178 
Other Assets   5,299    3,305 
Total Asset  $33,641   $52,070 
           
Liabilities & Stockholder’s Equity          
Liabilities          
Accounts Payable  $1,563   $1,365 
Deferred Revenue   7,254    6,238 
Debt Payable   15,134    14,837 
Other Liabilities   8,224    5,559 
Total Liabilities  $32,175   $27,999 
Shareholder’s Equity  $1,466   $24,071 
Total Liabilities & Stockholder’s Equity  $33,641   $52,070 

 

7

 

 

AUGMEDIX, INC.

Condensed Consolidated Statement of Cash Flows

(Unaudited, in thousands)

 

   Three Months Ended   Year Ended 
   December 31,   December 31, 
   2022   2021   2022   2021 
                 
Cash Flows used in Operating Activities  $(4,386)  $(5,282)  $(16,773)  $(18,592)
Cash Flows used in Investing Activities   (592)   (188)   (1,408)   (611)
Cash Flows from / (used in) Financing Activities   7    35,946    (1,237)   37,827 
Effect of exchange rate changes on cash and restricted cash   (38)   (7)   (181)   (10)
Net Increase / (decrease) in Cash  $(5,009)  $30,469   $(19,599)  $18,614 
Cash and Restricted Cash at the beginning of the period  $26,997   $11,118   $41,587   $22,973 
Cash and Restricted Cash at the end of the period  $21,988   $41,587   $21,988   $41,587 

 

 

 

8

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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augx-20230327.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 augx-20230327_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 augx-20230327_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Mar. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 27, 2023
Entity File Number 001-40890
Entity Registrant Name AUGMEDIX, INC.
Entity Central Index Key 0001769804
Entity Tax Identification Number 83-3299164
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 111 Sutter Street
Entity Address, Address Line Two Suite 1300
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code 888
Local Phone Number 669-4885
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AUGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea175782-8k_augmedix_htm.xml IDEA: XBRL DOCUMENT 0001769804 2023-03-27 2023-03-27 iso4217:USD shares iso4217:USD shares 0001769804 false 8-K 2023-03-27 AUGMEDIX, INC. DE 001-40890 83-3299164 111 Sutter Street Suite 1300 San Francisco CA 94104 888 669-4885 false false false false Common Stock, $0.0001 par value per share AUGX NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://augmedix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea175782-8k_augmedix.htm augx-20230327.xsd augx-20230327_lab.xml augx-20230327_pre.xml ea175782ex99-1_augmedix.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea175782-8k_augmedix.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea175782-8k_augmedix.htm" ] }, "labelLink": { "local": [ "augx-20230327_lab.xml" ] }, "presentationLink": { "local": [ "augx-20230327_pre.xml" ] }, "schema": { "local": [ "augx-20230327.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AUGX", "nsuri": "http://augmedix.com/20230327", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea175782-8k_augmedix.htm", "contextRef": "From2023-03-27to2023-03-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://augmedix.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea175782-8k_augmedix.htm", "contextRef": "From2023-03-27to2023-03-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001213900-23-022948-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-022948-xbrl.zip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

P?DVI_(2I=@ 8:.U1;"XMHVJ(7;RF!"^-7+60 MVK-( 6^QGA-T+9XII>Q)8\2:9+V]4@[5GLF#>5ZVMGKS'=ZRM1H8#B^0W*"3 MUQHKCYOEZ]Z46I1C3;" 9E^@V<@AN** 0$"Q]+*<3:-*5;1:;B*6K=830X2; MQ$LE/Q'_9CV#JVH;!FB.]V\!S;Y LQU)>W)V/\ .1Q?8AG;3:*B"=E1-A2%V M190J^I3S PW@1GNB_-H<-%I+::M/Q$W$L&^I;G^C[0*BCB/[V9DBZZ7!]:)G MBNR94G^9/5.>TBWCH/JHX%5JMD$WW\H^@-37W'=8=#'3YJ\HSM!"91O-46*F M*[JB9# 7BZXH15>4HBO*&MGEZ3/>^PXL1=RP?A'>FX%R_$K$5C=%@J(%1WY: M<.S+<@OJYKW!RJK.#SOIF[$0B'SW^TAY&/8#[G0F\W[ WE)<5T.0+ MFDT?EAFR5AHH>8&%%5I-'.3:ZK!D?9$'^;&4N4[^H]- M+[>5F[3:6FX\^VI^#QIHZA^W $%V [*L/UYW+\_U6OFM*J_W\A@Y[;GF\:+-+4Y7F MR_4WJ$#[YKX8G?>)V-"R!.!-Z91S0CB[4F_G!%5V9_?-"7/LSB*>$WC(5_CS MY*SCZL"Y!K'N';?H+N>_8[>TMNW%TFWUT MW ?SD=OA;^@6JZRNAB/+F9 0_@#:0]\$(0SSL0O=-P;!:/]] M>BDF>7%>S6IQ'T+!!6OC@EWU UR0F7S>^ROPR$C/Y.G.;5;FZYJBOL2^L56E M\;/M4_=QV6I+J;=77H)^@.NN*UKE)]F\:.)80)-;:';7+I=:9(6=$^YF.B<\ M$46IS3X'.S6E6=ET;"$+''""9+FQ:.-PJ VEW=QT$"H3()JBIB^]REN@17A3 M=ATV3+?UV%FH+C?I>>G6&[N")-U,(R>.P,(%6 RH]FV,DB2O'D 90RQ\ .^ M" ^0FFZ_\^)P4'#!NK@@/WY B?/($VBLZ!ZW?S2K*8UT5/_%<6Y5J376<['; M/F,!S,S6:L_AX:-!5=IK:C>4R[)Q<0E@V/G\DXMY,V!Q@%ZVM\[?FE))WZ/\ M,GIN5!55?:ZW?\^7K@+9:RM5C@-=>T69TR9OU[U6%MNGD0HEY,T7NJE@TY9S MK5'.X.9YM7$PFN4,.;Z;!Z->SE ]L TP,G@!7VWV ,UQF*> 9E^@V7% [MN( M8W-E^R&,:&PR)-=6:AMWWF>!HZG4T]E&NP@--I2JMNDF'%D T0 C14@NVR9O MY"%"II-NJ[@H85='2MGW>R^^);Q3W MQ,M[XAO%/?$YO"=^L_->.'8/#V%T4-K$J&19?- M'6E_/^#KT3^!FM4*?D;D[<$UY9O&JK9^K&[B;NI\+W?;=U-G,0Y/SLX] MC_LKXK0)Q"QQ /[LZUNZ=+O9F'LY\87N#=BO^G!TRNCCU=^!^:A;0+Y>& 2_Z'KL#<0^4!_MJX\T%&TJUGIN@:W-> M3XY\1>T7.N"_^0,XGZ=%V?YZ&>N*]A.-H _%UUI5JI7U=.G?47 H<9DH<>;> MNI2JV'7@A2:SUS6ETEQ'-GN1-_IBU MLZZO!?V7MJ\<:+EQU)J*/G,3T*R=/V?W"K9\V+KBEK-#4W4 MFM*JYO["#6&G;O&@ =BTW-"HKM2SM([>^+X)M7><[AVKE%6M;MKS%#=AO/T\ MN3*5;VB*NO$[5#.6;[33[H=\[:2%CJ#[@>[RI8KUEATBZ[D>2U5JC<9^>H36 M@P M4SW]GGB#GF,/[IWCI' :K=-IM,XL+7O0]_P@ND*$3]T7+&7I'Z5:1^+4L\Z0Q'C@/2L% M[&#SU+*N&72;Z9>O:TJUE7(>+ITA M=>?2+L"N*UJZS7S^P58;2C-=);P'<.,E7<_"]Y9BFW-VW+7]R+T%.VY30:S7 M<["TA*0; T--IX/O! REEK[B;!> --0,3=AVUOQNM*NI4ZG74$#[*QER2+8.#M7FTI+VV8ZPT_WP+GJ][E!ODG^ MPQCH]@-GH UQ)CY[S+&9@9M MWO,!:GMF@;=7P#?[2@RN<9<]=?I?*"G]@79 MZ^4__Z:"0UB]VGI^9/H@UO_\&QKR=DG45^Z#5FFXU%D1#ND>%Y_?H+IYL3M9 MM9XL"K"I*I7G5Q;MBE?7L_AJ1:DU]K2L:DWD5]M@X[U4^H.!VU!7WKZ=YQ0B MB=Z+4(VZB]4H\9W/_ %G7?Y@VC;:$Z",X1 M5554]?E:Y@%@8'X=^4O"@*8I[9_H0)BOC-U:%EG&X:^_8C>[Y+SPWMY4]-W=CB;*+ M^.+MAV^7_SK##Y\[7V[._A]02P$"% ,4 " "O.'M6R!?%+E0# "Y# M$0 @ $ 875G>"TR,#(S,#,R-RYX"TR,#(S M,#,R-U]L86(N>&UL4$L! A0#% @ KSA[5BIX$G17!P U5< !4 M ( !M X &%U9W@M,C R,S S,C=?<')E+GAM;%!+ 0(4 Q0 ( M *\X>U:MG$:6*10 $>A 8 " 3X6 !E83$W-3"YH=&U02P$"% ,4 " "O.'M6%_5K'+TE #"D $ &P M @ &=*@ 96$Q-S4W.#)E>#DY+3%?875G;65D:7@N:'1M4$L% 3!@ % 4 5 $ )-0 $! end